Calliditas Therapeutics AB (publ)
CALT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 50.3% | 250.1% | 26,141.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $0 | $0 |
| % Margin | 93.6% | 98.1% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $0 | $0 |
| Sales & Mktg Exp. | $1 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $1 | $1 | $0 |
| Operating Income | -$0 | -$0 | -$1 | -$0 |
| % Margin | -31.9% | -52.6% | -228.7% | -43,446.2% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$1 | -$0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$1 | -$0 |
| % Margin | -38.6% | -51.3% | -222.2% | -49,944.1% |
| EPS | -17.38 | -15.56 | -20.04 | -19.46 |
| % Growth | -11.7% | 22.4% | -3% | – |
| EPS Diluted | -17.38 | -15.56 | -20.04 | -19.46 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -30.5% | -48.4% | -205.7% | -43,409.4% |